AMARIN CORP PLC\UK SEC Filings

Amarin Corporation reported Q2 2026 net revenue of $42,211 (amounts in thousands), down from $72,741 a year earlier, as product sales softened and prior-year licensing milestones did not recur. Cost of goods sold rose to $27,222, compressing gross margin to $14,989 and driving an operating loss of $12,010.

Net loss narrowed to $7,650 for the quarter and $18,162 for the first half of 2026, helped by lower operating expenses and higher interest income. Cash and short-term investments totaled $314.6 million within total assets of $624.4 million at June 30, 2026, and the company had no debt, with net cash provided by operating activities of $12,992 year-to-date.

The 2025 Global Restructuring Plan is effectively winding down, with cumulative restructuring charges of $39.6 million and a remaining liability of $2,587 (in thousands). Litigation-related charges were $6.3 million in Q2, including a confidential settlement with certain purchaser plaintiffs, while VASCEPA/VAZKEPA remains the core cardiovascular franchise across U.S., European and other global markets.

Amarin Corporation plc reported Q2 2026 results with total net revenue of $42.2 million and a net loss of $7.7 million, compared with $72.7 million and a $14.1 million loss in Q2 2025. The revenue decline mainly reflects the absence of a $25 million upfront payment from the Recordati licensing agreement in the prior-year quarter, along with modest declines in U.S. and European product revenue amid generic competition and the shift to a partnered model.

Profitability metrics improved despite lower revenue. Operating expenses fell to $27.0 million, down 59% year over year, as a $70 million annual cost-savings program and restructuring tied to the Recordati partnership were completed, narrowing the operating loss to $12.0 million. Non-GAAP net income was $790 thousand. Cash reached $314.6 million at June 30, 2026, up from $302.6 million at December 31, 2025, and the company remained debt free while reducing inventories.

Operational trends were strong internationally and stable in the U.S. In-market demand for VASCEPA/VAZKEPA grew 59% across the global partner network, including 69% growth in Europe and 90% year-to-date growth in China. The U.S. IPE market share increased to 48% from 43%, VASCEPA prescriptions rose 14%, and management expects U.S. volumes to remain consistent in 2026 alongside continued international growth and positive cash flow generation.

Amarin Corporation plc SVP & CFO Peter L. Fishman acquired 2,447 American Depositary Shares (ADS) on July 1, 2026 through the vesting and settlement of equity awards. To cover related taxes, 1,206 ADS were withheld by the company at $15.94 per ADS, which was not a market sale. Following these transactions, he directly holds 7,461 ADS. These awards relate to 4,894 RSUs granted on January 10, 2025 under the 2020 Stock Incentive Plan, vesting in two tranches through July 1, 2026.

Amarin Corporation executive David Paul Keenan, EVP and Chief Operating Officer, reported equity-compensation activity in American Depositary Shares (ADSs) tied to vesting of Restricted Stock Units granted on 10 January 2025. On 1 July 2026, 1,926 ADSs were withheld to satisfy taxes and 3,688 RSUs linked to ADSs were reported. After these transactions he directly holds 13,470 ADSs.

AMARIN CORP PLC reported compensation-related equity activity for EVP and Chief Scientific Officer Steven B. Ketchum. On July 1, 2026 he acquired 3,688 American Depositary Shares through a derivative exercise linked to restricted stock units, while 1,887 ADS were disposed as shares withheld to cover tax obligations. Following these events, he directly holds 42,680 ADS.

Amarin Corporation EVP and Chief Legal Officer Jonathan Provoost reported equity compensation activity dated July 1, 2026. He acquired 3,688 American Depositary Shares (ADS) in connection with Restricted Stock Units (RSUs), while 1,264 ADS were withheld to cover tax obligations, which the company notes is not a market sale. The disclosure also references RSU awards, including a 7,376-unit grant vesting in two tranches in 2026, with each RSU representing a contingent right to receive twenty ordinary shares or cash.

AMARIN CORP PLC (AMRN) President and CEO Aaron Berg reported routine equity compensation activity involving Restricted Stock Units (RSUs) and related tax withholding. On June 26, 2026, 6,250 RSUs converted into 6,250 American Depositary Shares (ADSs), recorded as an option/RSU exercise with a transaction price of $0.00 per ADS.

To cover tax obligations from this vesting, the issuer withheld 3,197 ADSs at $16.35 per ADS, a non-market disposition coded as tax withholding under Rule 16b-3. Following these transactions, Berg directly held 88,845 ADSs. A footnote explains that one ADS represents twenty ordinary shares and that the amounts shown already reflect this ADS ratio change.

Amarin Corporation plc reports that at its Annual General Meeting, shareholders re-elected all director nominees and approved the non-binding Say-on-Pay proposal, but several key capital and governance measures failed. Proposals to authorize the Board to issue shares up to a nominal £37,750,000, to increase the 2020 Stock Incentive Plan reserve by 15,000,000 Ordinary Shares, to disapply UK statutory pre-emption rights on up to £20,970,000 of share capital, and to permit electronic delivery of meeting materials were not approved. The Board states that, without these approvals, its ability to grant equity incentives to employees and directors is highly limited, so it expects most future annual incentive compensation to be paid in cash, which will affect the company’s total cash position. Amarin also expects to continue incurring printing and mailing costs for paper proxy materials. Turnout was substantial, with 295,122,317 Ordinary Shares, about 70% of the 419,458,656 shares entitled to vote as of the record date, present in person or by proxy.

Amarin Corporation reported a Q1 2026 net loss of $10.5 million, improving from $15.7 million a year earlier, as revenue edged up and operating costs fell. Total revenue reached $45.1 million, including $43.3 million of product sales and $1.8 million of licensing and royalty income.

Gross margin declined as cost of goods sold rose to $27.4 million, but selling, general and administrative expenses dropped sharply to $21.1 million, partly reflecting restructuring. The company recorded $3.3 million of restructuring expense and $3.1 million of litigation settlements. Amarin ended the quarter with $307.8 million in cash and short‑term investments, total assets of $645.8 million, and no debt, while generating $6.4 million of cash from operating activities.